| Literature DB >> 30357468 |
M C Jong1,2, I Boers3, H A van Wietmarschen3, E Tromp4, J O Busari5, R Wennekes5, I Snoeck6, J Bekhof6, A M Vlieger4.
Abstract
Many children suffer from headaches. Since stress may trigger headaches, effective techniques to cope with stress are needed. We investigated the effectiveness of two mind-body techniques, transcendental meditation (TM) or hypnotherapy (HT), and compared them with progressive muscle relaxation (PMR) exercises (active control group). Children (9-18 years) suffering from primary headaches more than two times per month received either TM (N = 42), HT (N = 45) or PMR (N = 44) for 3 months. Primary outcomes were frequency of headaches and ≥ 50% reduction in headaches at 3 and 9 months. Secondary outcomes were adequate relief, pain coping, anxiety and depressive symptoms, somatisation and safety of treatment. Groups were comparable at baseline. Headache frequency was significantly reduced in all groups from 18.9 days per month to 12.5 and 10.5 at respectively 3 and 9 months (p < 0.001), with no significant differences between the groups. Clinically relevant headache reduction (≥ 50%) was observed in 41% and 47% of children at 3 and 9 months respectively, with no significant differences between the groups. No differences were observed in secondary outcome measures between the intervention groups. No adverse events were reported.Entities:
Keywords: Children; Headache; Hypnotherapy; Meditation; Pain; Relaxation
Mesh:
Year: 2018 PMID: 30357468 PMCID: PMC6339662 DOI: 10.1007/s00431-018-3270-3
Source DB: PubMed Journal: Eur J Pediatr ISSN: 0340-6199 Impact factor: 3.183
Fig. 1Flow diagram of children in the study
Demographic and clinical characteristics of children in the study
| Characteristics | Value | All (N = 131) | HT ( | TM ( | PMR ( |
|---|---|---|---|---|---|
| Age (year) | Average age ± SD | 13.3 ± 2.5 | 13.0 ± 2.3 | 13.9 ± 2.4 | 12.9 ± 2.7 |
| Gender, | Boys | 30 (23%) | 7 (16%) | 9 (21%) | 14 (32%) |
| Girls | 101 (77%) | 38 (84%) | 33 (79%) | 30 (68%) | |
| Hospital, | Atrium | 23 (18%) | 8 (18%) | 7 (17%) | 8 (18%) |
| CWZ | 9 (7%) | 3 (7%) | 3 (7%) | 3 (7%) | |
| Antonius | 27 (21%) | 10 (22%) | 9 (21%) | 8 (18%) | |
| Isala | 46 (35%) | 14 (31%) | 15 (36%) | 17 (39%) | |
| MMC | 6 (5%) | 3 (7%) | 1 (2%) | 2 (5%) | |
| JKZ | 20 (15%) | 7 (16%) | 7 (17%) | 6 (14%) | |
| Diagnosis, | Migraine | 21 (16%) | 7 (16%) | 7 (17%) | 7 (16%) |
| Tension-type headache | 79 (60%) | 30 (67%) | 24 (55%) | 26 (59%) | |
| Migraine/tension type | 23 (18%) | 6 (13%) | 8 (19%) | 9 (21%) | |
| Chronic daily headache | 7 (5%) | 2 (4%) | 3 (7%) | 2 (5%) | |
| Cluster headache | 1 (1%) | – | 1 (2%) | – | |
| Headache duration | Years, average score ± SD | 2.8 ± 2.9 | 3.0 ± 3.1 | 2.5 ± 2.8 | 2.8 ± 2.7 |
| Headache frequency | Number of headaches per month, average number ± SD | 18.4 ± 9.4 | 18.2 ± 9.6 | 19.5 ± 8.7 | 17.7 ± 10.1 |
| Headache severity | Average score ± SD | 3.2 ± 0.6 | 3.2 ± 0.6 | 3.1 ± 0.6 | 3.1 ± 0.7 |
| RADS | Total score (anxiety and depression), average ± SD | 14.8 ± 8.3 | 15.9 ± 8.5 | 13.5 ± 8.3 | 14.9 ± 8.0 |
| Total anxiety score, average ± SD | 7.7 ± 4.8 | 8.4 ± 5.0 | 7.0 ± 4.8 | 7.8 ± 4.7 | |
| Total depression score, Average ± SD | 6.4 | 6.9 ± 3.8 | 5.8 ± 3.6 | 6.5 ± 3.5 | |
| PCQ | Average score ± SD | 99.6 ± 17.4 | 95.6 ± 14.2 | 102.1 ± 19.9 | 101.4 ± 17.5 |
| CSI | Average score ± SD | 20.7 ± 14.1 | 22.5 ± 12.4 | 19.7 ± 16.6 | 19.6 ± 13.3 |
Full analysis set of all randomised children into the study
Primary and secondary outcome measures after 3 and 9 months of intervention: ITT analyses
| Outcome variable | All (N = 123) | HT (N = 45) | TM (N = 37) | PMR (N = 41) | Difference versus baseline ( | Difference between interventions ( |
|---|---|---|---|---|---|---|
| Number of days with headache per 4 weeks (mean ± SD) | ||||||
| Baseline | 18.9 (9.5) | 18.2 (9.6) | 20.1 (9.0) | 18.5 (9.8) | – | 0.64b |
| 3 months | 12.5 (8.8) | 12.1 (9.4) | 13.2 (9.6) | 12.3 (7.6) |
| 0.85b |
| 9 months | 10.5 (9.0) | 9.8 (9.8) | 11.8 (9.1) | 10.0 (7.9) |
| 0.57b |
| ≥ 50% reduction in headache frequency (%) | ||||||
| Baseline | – | – | – | – | – | – |
| 3 months | 50 (41%) | 20 (44%) | 15 (41%) | 15 (37%) | – | 0.76c |
| 9 months | 58 (47%) | 24 (53%) | 17 (46%) | 17 (42%) | 0.17d | 0.54c |
aPaired t test
bOne-sided ANOVA
cChi-squared test
dMcNemar test
Italicized p-values indicate a statistically significant difference
Secondary outcome measures after 3 and 9 months of intervention: ITT analysis
| Outcome variable | All (N = 123) | HT (N = 45) | TM (N = 37) | PMR (N = 41) | Difference versus baseline ( | Difference between interventions ( |
|---|---|---|---|---|---|---|
| Adequate relief (%) | ||||||
| Baseline |
|
|
|
| – | – |
| 3 months | 39 (32%) | 19 (42%) | 10 (27%) | 10 (24%) | – | 0.16c |
| 9 months | 53 (43%) | 24 (53%) | 13 (35%) | 16 (39%) |
| 0.21c |
| RCADS (total) (mean ± SD) | ||||||
| Baseline | 14.5 (8.3) | 15.9 (8.5) | 12.5 (7.9) | 14.7 (8.2) | – | 0.12b |
| 3 months | 13.8 (9.4) | 14.9 (10.1) | 12.4 (9.6) | 13.8 (8.5) | 0.53a | 0.11b |
| 9 months | 12.4 (9.0) | 13.5 (10.0) | 11.0 (8.2) | 12.3 (8.5) | 0.06a | 0.16b |
| RCADS (anxiety) (mean ± SD) | ||||||
| Baseline | 7.6 (4.8) | 8.4 (5.0) | 6.4 (4.5) | 7.6 (4.8) | – | 0.28b |
| 3 months | 7.4 (5.4) | 8.0 (5.6) | 6.5 (5.4) | 7.6 (5.2) | 0.80a | 0.24b |
| 9 months | 6.5 (5.1) | 6.9 (5.5) | 5.8 (4.8) | 6.8 (5.1) | 0.11a | 0.31b |
| RCADS (depression) (mean ± SD) | ||||||
| Baseline | 6.3 (3.6) | 6.9 (3.8) | 5.5 (3.5) | 6.4 (3.6) | – | 0.07b |
| 3 months | 5.8 (3,9) | 6.4 (4.5) | 5.2 (3.8) | 5.7 (3.4) | 0.30a | 0.16b |
| 9 months | 5.3 (3,8) | 6.0 (4.3) | 4.8 (3.3) | 5.0 (3.4) |
| 0.15b |
| PCQ (mean ± SD) | ||||||
| Baseline | 99.4 (17.8) | 95.5 (14.2) | 101.5 (21.1) | 101,8 (17.8) | – | 0.19b |
| 3 months | 98.1 (19.9) | 97.0 (19.6) | 97.3 (21.0) | 100.1 (19.6) | 0.32a | 0.75b |
| 9 months | 97.7 (19.2) | 96.4 (20.4) | 97.6 (18.8) | 99.3 (18.4) | 0.27a | 0.78b |
| CSI (mean ± SD) | ||||||
| Baseline | 20.3 (13.7) | 22.5 (12.4) | 18.4 (15.3) | 19.6 (13.5) | – | 0.36b |
| 3 months | 17.3 (13.6) | 17.9 (13.0) | 17.3 (15.2) | 16.7 (12.9) |
| 0.92b |
| 9 months | 15.6 (12.2) | 16.0 (12.3) | 15.5 (13.2) | 15.2 (11.5) |
| 0.94b |
aPaired t test
bOne-sided ANOVA
cChi-squared test
dMcNemar test
ep values were corrected for baseline differences between the groups if these were present
Italicized p-values indicate a statistically significant difference
|
| |
|
|